Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tcm-MIBI
1998

Detecting Drug Resistance in Leukaemia with 99Tcm-MIBI

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): A Gruber, I Arestrom, D Xu, J Liliemark, SA Larsson, H Jacobsson

Primary Institution: Karolinska Hospital

Hypothesis

Can 99Tcm-MIBI be used as a marker for mdrl gene expression in leukaemic cells and can cyclosporin A modify its accumulation?

Conclusion

99Tcm-MIBI can effectively detect low levels of mdrl gene expression in leukaemic cells and its accumulation can be significantly increased by cyclosporin A.

Supporting Evidence

  • 99Tcm-MIBI accumulation was significantly higher in mdrl-negative cells compared to mdrl-positive cells.
  • CyA increased 99Tcm-MIBI accumulation by 30% in mdrl-negative cells and 242% in mdrl-positive cells.
  • The study confirms the high sensitivity of 99Tcm-MIBI for detecting P-glycoprotein expression.

Takeaway

This study shows that a special substance called 99Tcm-MIBI can help doctors see if leukaemia cells are resistant to treatment, and a medicine called cyclosporin A can help it work better.

Methodology

Leukaemic cells from ten patients were incubated with 99Tcm-MIBI and daunorubicin, with and without cyclosporin A, to measure drug accumulation.

Limitations

The study had a small sample size and results may not be generalizable to all leukaemia patients.

Participant Demographics

Patients with acute myelocytic leukaemia, five with undetectable mdrl gene expression and five with varying levels of mdrl mRNA.

Statistical Information

P-Value

0.009

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication